Posted in Clinical Data Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer April 21, 2026 BioSpace A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal cell carcinoma trial. Clinical DataOncologyRead full story